Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB3909 in Relapsed or Refractory Mantle Cell Lymphoma
CTR20231930Phase 2Terminated
- Sponsor
- Jiangsu Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
- Start
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of TQB3909 in mantle cell lymphoma (MCL), sponsored by Jiangsu Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.. Started Jun 2023; status: terminated.
02
Drugs
TQB3909
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on CTR20231930.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20231930.